Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: Targeting Akt in cancer for precision therapy

Fig. 1

Timeline of key progresses in ER-, Bcr-Abl-, EGFR-, HER2- and Akt-targeted cancer therapy. Based on the identification of ER, Bcr-Abl, EGFR, HER2 and Akt in promoting tumorigenesis, ER-, Bcr-Abl-, EGFR- and HER2-targeted therapy have been approved for treating various types of cancer, while Akt inhibitors are still being evaluated in phase III clinical trials

Back to article page